Theranostics with somatostatin receptor antagonists in SCLC: Correlation of ⁶⁸Ga-SSO120 PET with immunohistochemistry and survival.

ABSTRACT: Rationale: Positron Emission Tomography (PET) using the somatostatin receptor 2 (SSTR2)-antagonist satoreotide trizoxetan (⁶⁸Ga-SSO120) is a novel, promising imaging modality for small-cell lung cancer (SCLC), which holds potential for theranostic applications. This study aims to correlate uptake in PET imaging with SSTR2 expression in immunohistochemistry (IHC) and to assess the prognostic value of ⁶⁸Ga-SSO120 PET at initial staging of patients with SCLC. Methods: We analyzed patients who underwent ⁶⁸Ga-SSO120 PET/CT during initial diagnostic workup of SCLC as part of institutional standard-of-care. SSTR2 expression in IHC was evaluated on a 4-level scale and correlated with normalized standardized uptake values and tumor-to-liver ratios (SUV

SUBMITTER: Mavroeidi IA 

PROVIDER: S-EPMC11413793 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature